Accuray (ARAY) Cash from Financing Activities (2010 - 2026)
Accuray's (ARAY) quarterly Cash from Financing Activities came in at $4.1 million in Q1 2026, up 158.0% year-on-year from $1.6 million in Q1 2025, and up 1557.45% quarter-over-quarter from -$282000.0 in Q4 2025.
Accuray (ARAY) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Accuray's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $4.1 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 158.0% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $4.9 million, a 156.4% increase from a year earlier, with the FY2025 full-year figure at -$4.3 million, down 7.62% from the prior year.
- Cash from Financing Activities rose to $4.1 million in Q1 2026 per ARAY's latest filing, from -$282000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $5.8 million in Q4 2024 and bottomed at -$15.5 million in Q1 2022.
- The 5-year median for Cash from Financing Activities is -$475000.0 (2025), against an average of -$1.1 million.
- Across the five-year window, Cash from Financing Activities slumped 336.5% in 2022 and jumped 2343.58% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $4.3 million in 2022, then plunged by 106.01% to -$257000.0 in 2023, then soared by 2343.58% to $5.8 million in 2024, then plunged by 104.89% to -$282000.0 in 2025, then surged by 1557.45% to $4.1 million in 2026.
- Per Business Quant, the three latest ARAY Cash from Financing Activities figures stand at $4.1 million (Q1 2026), -$282000.0 (Q4 2025), and -$475000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.89 Bn | 173.59 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 127.82 Bn | 124.94 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 107.49 Bn | 98.27 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 67.24 Bn | 65.78 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 48.02 Bn | 44.34 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 28.25 Bn | 27.14 Bn | 750.30 Mn | -25.00 Mn |
| 7 | GE HealthCare Technologies | 28.17 Bn | 25.89 Bn | 1.98 Bn | 21.00 Mn |
| 8 | Smith & Nephew | 26.72 Bn | 26.14 Bn | - | - |
| 9 | Koninklijke Philips | 25.31 Bn | 22.19 Bn | 2.07 Bn | -26.93 Mn |
| 10 | Accuray | 29,112.00 | -38.50 Mn | 25.29 Mn | 4.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.11 Mn |
| Mar 31, 2026 | 4.11 Mn |
| Dec 31, 2025 | -282,000.00 |
| Dec 31, 2025 | -282,000.00 |
| Sep 30, 2025 | -475,000.00 |
| Sep 30, 2025 | -475,000.00 |
| Mar 31, 2025 | 1.59 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Dec 31, 2024 | 5.77 Mn |
| Dec 31, 2024 | 5.77 Mn |
| Sep 30, 2024 | -2.17 Mn |
| Sep 30, 2024 | -2.17 Mn |
| Mar 31, 2024 | -3.26 Mn |
| Mar 31, 2024 | -3.26 Mn |
| Dec 31, 2023 | -257,000.00 |
| Dec 31, 2023 | -257,000.00 |
| Sep 30, 2023 | -1.50 Mn |
| Sep 30, 2023 | -1.50 Mn |
| Mar 31, 2023 | -1.59 Mn |
| Mar 31, 2023 | -1.59 Mn |